Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA: A Cancer J Clin. 2023;73(1):17–48.

Google Scholar 

Ansari D, Tingstedt B, Andersson B, Holmquist F, Sturesson C, Williamsson C, Sasor A, Borg D, Bauden M, Andersson R. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929–46.

Article  CAS  PubMed  Google Scholar 

Neoptolemos J, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;6(1759–5053 (Electronic)):333–48.

Article  Google Scholar 

Taieb J, Prager GW, Melisi D, Westphalen CB, D’Esquermes N, Ferreras A, Carrato A, Macarulla T. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. ESMO Open. 2020;5(1):e000587. https://doi.org/10.1136/esmoopen-2019-000587.

Article  PubMed  PubMed Central  Google Scholar 

Kokkali S, Tripodaki ES, Drizou M, Stefanou D, Magou E, Zylis D, Kapiris M, Nasi D, Georganta C, Ardavanis A. Biweekly gemcitabine/nab-paclitaxel as first-line treatment for advanced pancreatic cancer. In Vivo. 2018;32(3):653–7.

CAS  PubMed  PubMed Central  Google Scholar 

Pijnappel EN, Dijksterhuis WPM, van der Geest LG, de Vos-Geelen J, de Groot JWB, Homs MYV, Creemers GJ, Mohammad NH, Besselink MG, van Laarhoven HWM, Wilmink JW, Group DPC. First- and second-line palliative systemic treatment outcomes in a real-world metastatic pancreatic cancer cohort. J Natl Compr Canc Netw. 2021;20(5):443-450.e3.

Adamska A, Elaskalani O, Emmanouilidi A, Kim M, AbdolRazak NB, Metharom P, Falasca M. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer. Adv Biol Regul. 2018;68:77–87.

Article  CAS  PubMed  Google Scholar 

Ireland L, Santos A, Ahmed MS, Rainer C, Nielsen SR, Quaranta V, Weyer-Czernilofsky U, Engle DD, Perez-Mancera PA, Coupland SE, Taktak A, Bogenrieder T, Tuveson DA, Campbell F, Schmid MC, Mielgo A. Chemoresistance in pancreatic cancer is driven by stroma-derived insulin-like growth factors. Cancer Res. 2016;76(23):6851–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, King RJ, Abrego J, Goode GD, Dasgupta A, Illies AL, Gebregiworgis T, Dai B, Augustine JJ, Murthy D, Attri KS, Mashadova O, Grandgenett PM, Powers R, Ly QP, Lazenby AJ, Grem JL, Yu F, Matés JM, Asara JM, Kim JW, Hankins JH, Weekes C, Hollingsworth MA, Serkova NJ, Sasson AR, Fleming JB, Oliveto JM, Lyssiotis CA, Cantley LC, Berim L, Singh PK. MUC1 and HIF-1alpha signaling crosstalk induces anabolic glucose metabolism to impart gemcitabine resistance to pancreatic cancer. Cancer Cell. 2017;32(1):71-87.e7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Amrutkar M, Gladhaug I. Pancreatic cancer chemoresistance to gemcitabine. Cancers. 2017;9(11):157.

Article  PubMed  PubMed Central  Google Scholar 

van Roessel S, van Veldhuisen E, Klompmaker S, Janssen QP, Abu Hilal M, Alseidi A, Balduzzi A, Balzano G, Bassi C, Berrevoet F, Bonds M, Busch OR, Butturini G, Del Chiaro M, Conlon KC, Falconi M, Frigerio I, Fusai GK, Gagnière J, Griffin O, Hackert T, Halimi A, Klaiber U, Labori KJ, Malleo G, Marino MV, Mortensen MB, Nikov A, Lesurtel M, Keck T, Kleeff J, Pandé R, Pfeiffer P, Pietrasz D, Roberts KJ, Sa Cunha A, Salvia R, Strobel O, Tarvainen T, Bossuyt PM, van Laarhoven HWM, Wilmink JW, Groot Koerkamp B, Besselink MG, Association E.-AH-P-B. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncol 2020;6(11):1733–1740.

Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW, Cancer ESGFP. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304(10):1073–81.

Murphy JE, Wo JY, Ryan DP, Clark JW, Jiang W, Yeap BY, Drapek LC, Ly L, Baglini CV, Blaszkowsky LS, Ferrone CR, Parikh AR, Weekes CD, Nipp RD, Kwak EL, Allen JN, Corcoran RB, Ting DT, Faris JE, Zhu AX, Goyal L, Berger DL, Qadan M, Lillemoe KD, Talele N, Jain RK, DeLaney TF, Duda DG, Boucher Y, Fernández-Del Castillo C, Hong TS. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. 2019;5(7):1020–7.

Article  PubMed  PubMed Central  Google Scholar 

Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, Kouchakji E, Rocha F, Carrier E. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for thetreatment of locally advanced pancreatic cancer. ESMO Open. 2020;5(4):e000668. https://doi.org/10.1136/esmoopen-2019-000668.

Article  PubMed  PubMed Central  Google Scholar 

De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, Florio R, Grassadonia A, Cama A. Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical updates. Cancers (Basel). 2021;13(16):3946. https://doi.org/10.3390/cancers13163946.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fonseca BD, Diering GH, Bidinosti MA, Dalal K, Alain T, Balgi AD, Forestieri R, Nodwell M, Rajadurai CV, Gunaratnam C, Tee AR, Duong F, Andersen RJ, Orlowski J, Numata M, Sonenberg N, Roberge M. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling. J Biol Chem. 2012;287(21):17530–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chowdhury MK, Wu LE, Coleman JL, Smith NJ, Morris MJ, Shepherd PR, Smith GC. Niclosamide blocks glucagon phosphorylation of Ser552 on β-catenin in primary rat hepatocytes via PKA signalling. Biochem J. 2016;473(9):1247–55.

Article  CAS  PubMed  Google Scholar 

Kaushal JB, Bhatia R, Kanchan RK, Raut P, Mallapragada S, Ly QP, Batra SK, Rachagani S. Repurposing niclosamide for targeting pancreatic cancer by inhibiting Hh/Gli non-canonical axis of Gsk3β, Cancers (Basel). 2021;13(13).

Guo Y, Zhu H, Xiao Y, Guo H, Lin M, Yuan Z, Yang X, Huang Y, Zhang Q, Bai Y. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. Cell Death Dis. 2022;13(2):112.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borowiec BG, Birceanu O, Wilson JM, Mcdonald AE, Wilkie MP. Niclosamide is a much more potent toxicant of mitochondrial respiration than TFM in the invasive sea lamprey. Environ Sci Technol. 2022;56(8):4970–9.

Article  CAS  PubMed  Google Scholar 

Figarola JL, Singhal J, Singhal S, Kusari J, Riggs A. Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas. Oncotarget. 2018;9(97):36945–65.

Article  PubMed  PubMed Central  Google Scholar 

Pearson RD, Hewlett EL. Niclosamide therapy for tapeworm infections. Ann Intern Med. 1985;102(4):550–1.

Article  CAS  PubMed  Google Scholar 

Hang J, Chen Y, Liu L, Chen L, Fang J, Wang F, Wang M. Antitumor effect and metabonomics of niclosamide micelles. J Cell Mol Med. 2022;26(18):4814–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma R, Ma ZG, Gao JL, Tai Y, Li LJ, Zhu HB, Li L, Dong DL, Sun ZJ. Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy. J Biomed Mater Res A. 2020;108(1):30–8.

Article  CAS  PubMed  Google Scholar 

Ross KA, Brenza TM, Binnebose AM, Phanse Y, Kanthasamy AG, Gendelman HE, Salem AK, Bartholomay LC, Bellaire BH, Narasimhan B. Nano-enabled delivery of diverse payloads across complex biological barriers. J Control Release. 2015;219:548–59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

Article  Google Scholar 

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107(2):dju413.

Article  PubMed  Google Scholar 

Naqvi S, Mohiyuddin S, Gopinath P. Niclosamide loaded biodegradable chitosan nanocargoes: an. R Soc Open Sci. 2017;4(11):170611.

Article  PubMed  PubMed Central  Google Scholar 

Munoz E, Chen G, Hossain A, Wu S, Oceguera Nava E, Hang J, Lee T, Zhang Q, Wang G, Chen QH. Synthesis and biological evaluation of niclosamide PROTACs. Bioorg Med Chem Lett. 2022;72:128870.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mullis AS, Broderick SR, Binnebose AM, Peroutka-Bigus N, Bellaire BH, Rajan K, Narasimhan B. Data analytics approach for rational design of nanomedicines with programmable drug release. Mol Pharm. 2019;16(5):1917–28.

Article  CAS  PubMed  Google Scholar 

Huntimer L, Ramer-Tait AE, Petersen LK, Ross KA, Walz KA, Wang C, Hostetter J, Narasimhan B, Wannemuehler MJ. Evaluation of biocompatibility and administration site reactogenicity of polyanhydride-particle-based platform for vaccine delivery. Adv Healthc Mater. 2013;2(2):369–78.